Literature DB >> 11602081

Treatment of coexisting diabetes and hypertension.

N M Kaplan1.   

Abstract

The rapidly growing number of patients with coexisting diabetes and hypertension must be intensively treated to protect them from their very high risk for premature cardiovascular morbidity and mortality. After careful ascertainment of their out-of-the-office blood pressure, and testing for postural hypotension, therapy should consist of both lifestyle modifications and antihypertensive drugs. Usually, two or more such drugs are needed to bring blood pressure below the 130/85 mm Hg level. In addition, control of hyperglycemia and dyslipidemia is usually required. Despite the costs and difficulties of achieving adequate control of these diseases, such patients can be protected from the debilities of diabetes and hypertension.

Entities:  

Mesh:

Year:  2001        PMID: 11602081     DOI: 10.1007/s11886-001-0072-3

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  48 in total

1.  Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study.

Authors:  P Gaede; P Vedel; H H Parving; O Pedersen
Journal:  Lancet       Date:  1999-02-20       Impact factor: 79.321

2.  Improvement of insulin sensitivity contributes to blood pressure reduction after weight loss in hypertensive subjects with obesity.

Authors:  T Ikeda; T Gomi; N Hirawa; J Sakurai; N Yoshikawa
Journal:  Hypertension       Date:  1996-05       Impact factor: 10.190

3.  Adverse effects of hyperglycemia on kidney development in rats: in vivo and in vitro studies.

Authors:  K Amri; N Freund; J Vilar; C Merlet-Bénichou; M Lelièvre-Pégorier
Journal:  Diabetes       Date:  1999-11       Impact factor: 9.461

Review 4.  Management of hypertension in patients with type 2 diabetes mellitus: guidelines based on current evidence.

Authors:  N M Kaplan
Journal:  Ann Intern Med       Date:  2001-12-18       Impact factor: 25.391

5.  Insulin sensitivity and regular alcohol consumption: large, prospective, cross sectional population study (Bruneck study)

Authors:  S Kiechl; J Willeit; W Poewe; G Egger; F Oberhollenzer; M Muggeo; E Bonora
Journal:  BMJ       Date:  1996-10-26

6.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors:  H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

7.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

8.  Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study.

Authors:  C E Mogensen; S Neldam; I Tikkanen; S Oren; R Viskoper; R W Watts; M E Cooper
Journal:  BMJ       Date:  2000-12-09

9.  High normal blood pressure, hypertension, and the risk of type 2 diabetes in Japanese men. The Osaka Health Survey.

Authors:  T Hayashi; K Tsumura; C Suematsu; G Endo; S Fujii; K Okada
Journal:  Diabetes Care       Date:  1999-10       Impact factor: 19.112

10.  The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide.

Authors:  H Buter; M H Hemmelder; G Navis; P E de Jong; D de Zeeuw
Journal:  Nephrol Dial Transplant       Date:  1998-07       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.